These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials.
    Author: Szuba A, Podgórski M.
    Journal: Pharmacol Rep; 2006; 58 Suppl():16-20. PubMed ID: 17332667.
    Abstract:
    There is a growing clinical evidence to support the hypothesis that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase is a new independent cardiovascular risk factor. ADMA mediates endothelial dysfunction in lipid disorders, coronary artery disease, chronic heart failure, diabetes mellitus and hypertension. The aim of this review was to summarize the latest evidence from epidemiological and prospective clinical trials and to emphasize the role of ADMAas a cardiovascular risk factor.
    [Abstract] [Full Text] [Related] [New Search]